BRAF and cancer: While current opinion is that nodules with a RAS variant (with or without TERT promoter variant) should be surgically removed given their potential malignant or pre-malignant status, it is unclear if cancers harboring a TERT promoter variant plus a RAS or BRAF variant should be treated differently based on this genomic information independent from traditional prognostic factors for risks of recurrence and death, especially among lower-risk patients (42).